How Far We've Come: AI, ML Applications In Practice

In this segment from the Bioprocess Online Live event, How Computational Biology Speeds Drug Discovery, Development, our guests Tina Larson, President and COO at Recursion, and Andrew Satz, CEO and co-founder at EVQLV discuss the state of AI and ML adoption for drug discovery applications in biotech. They also reflect on some of the efficiency gains these tools have enabled to chip away at the long journey from discovery to clinic.